Evommune, Inc. files regulatory documents covering its clinical-stage biotechnology business, public-company governance and capital structure. Its 8-K filings furnish operating and financial results, Regulation FD corporate presentations, material-event disclosures and clinical updates for pipeline programs including EVO756 and EVO301.
Evommune’s SEC record also includes registration materials tied to common stock offerings and proxy materials for annual meeting matters. These filings document director elections, auditor ratification, shareholder voting procedures, capital-structure disclosures, material agreements, clinical and regulatory disclosures, and risk factors associated with developing therapies for chronic inflammatory diseases.
Evommune, Inc. filed a prospectus supplement to its S-1 that incorporates its Form 10-Q for the quarter ended March 31, 2026 and updates the offering materials.
The supplement discloses cash, cash equivalents and investments of approximately $307.0 million, a net loss of $21.7 million ($0.64 per share) for Q1 2026, and 36,018,372 shares outstanding as of May 5, 2026. The Company raised net proceeds of $117.2 million in February 2026 from a private placement of 4,494,279 shares at $27.88 per share and states existing resources are expected to fund operations through 2028 under its current plan.
The supplement reiterates clinical development plans: EVO756 Phase 2b CSU initial results expected June 2026, EVO756 AD initial results expected Q3 2026, planned EVO756 migraine Phase 2b start mid-2026, and EVO301 Phase 2b planned to commence mid-2027.
Evommune, Inc. reported a larger net loss for the quarter ended March 31, 2026 as it continued investing heavily in its anti-inflammatory pipeline. The company generated no revenue this quarter, compared with $3.0 million of license revenue a year earlier.
Research and development expenses rose to $17.3 million and general and administrative costs to $6.6 million, driving a net loss of $21.7 million, or $0.64 per share. Cash, cash equivalents and investments totaled $307.0 million, helped by a $117.2 million private placement, which management believes can fund operations through 2028.
The company’s lead programs, EVO756 and EVO301, are in Phase 2 development targeting chronic inflammatory diseases, with multiple Phase 2b trials underway or planned over the next several years.
Evommune, Inc. reported first-quarter 2026 results and detailed progress across its chronic inflammation pipeline. Cash, cash equivalents and investments were $307.0 million as of March 31, 2026, up from $216.7 million at year-end 2025, supporting an expected cash runway through 2028.
The company reported no revenue in Q1 2026 versus $3.0 million a year earlier, driven by lower collaboration revenue, and a net loss of $21.7 million, compared with $14.6 million in Q1 2025, as R&D and G&A spending increased.
Evommune highlighted late-stage pipeline catalysts: Phase 2b top-line data for EVO756 in chronic spontaneous urticaria is expected in June 2026 and in atopic dermatitis in the third quarter of 2026, with a Phase 2b migraine prophylaxis trial planned for mid-2026. For EVO301, positive Phase 2a proof-of-concept data in atopic dermatitis support a larger Phase 2b trial using a new subcutaneous formulation planned to start in mid-2027.
Evommune, Inc. registers 4,494,279 shares of common stock for resale by selling stockholders.
The prospectus covers the resale from time to time of up to 4,494,279 Shares by the selling stockholders; the company will not receive proceeds from these resales. Shares outstanding were 36,018,372 as of March 31, 2026.
Evommune, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 2, 2026 at 11:30 a.m. Eastern Time. The proxy seeks election of two Class I directors, Luis Peña and Eugene A. Bauer, M.D., and ratification of BDO USA, P.C. as independent auditor for 2026.
Stockholders of record as of April 6, 2026 can attend and vote online using a 16-digit control number. The filing details board structure and independence, committee responsibilities, executive roles, and 2025 compensation, including salary, bonus and equity awards, as well as BDO’s 2025 audit fees.
Patel Jeegar Pravinkumar reported acquisition or exercise transactions in this Form 4 filing.
Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel received an employee stock option grant for 69,315 shares of common stock. The option has a strike price of $26.77 per share and expires on April 15, 2036, with no cash paid for the grant itself.
According to the vesting terms, one quarter of the option vests on the first anniversary of the grant date. The remaining three quarters vest in 36 equal monthly installments, contingent on Patel’s continuous service with the company. After this award, he holds 69,315 derivative securities directly.
Evommune, Inc. reported that Chief of Development Operations Janice Suzann Drew received an employee stock option grant covering 73,892 shares of common stock. The options carry an exercise price of $26.77 per share and expire on April 15, 2036.
According to the vesting terms, one fourth of the options will vest on the first anniversary of the grant date, with the remaining options vesting in 36 equal monthly installments thereafter, contingent on continued service. Following this grant, the reporting person holds 73,892 stock options directly.
Evommune, Inc. reported that Chief Medical Officer Eugene Bauer received an award of employee stock options covering 51,117 shares of common stock. The options have an exercise price of $26.77 per share and expire on April 15, 2036.
One quarter of the options vest on the first anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments, contingent on his continued service. Following this grant, Bauer holds 51,117 derivative securities directly.